Fig. 1 · Structure

Documents & Downloads

AdipoRon

Cat. No. A13768 CAS 924416-43-3

AdipoR1 and AdipoR2 agonist

AdipoRon is a novel small-molecule AdipoR agonist; binds to both AdipoR1(Kd= 1.8 uM) and AdipoR2(Kd=3.1 uM). IC50 value: 1.8/3.1 uM(AdipoR1/2, Kd)

In Stock

Publications for AdipoRon

4 publications citing this product

  1. Zongmeng Zhang, .et al. , Biocell, 2026, 50(1):1-10
  2. Weidong Yan, .et al. , Pharmaceutics, 2022, Nov 15;14(11):2467 PMID: 36432657
  3. Yunjing Yan, .et al. , J Pathol, 2022, Jun;257(2):146-157 PMID: 35072951
  4. Uchida T, .et al. , J Ocul Pharmacol Ther, 2019, Aug 28 PMID: 31460821

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AdipoRon bound human AdipoR1 and AdipoR2 in a surface plasmon resonance assay, with reported Kd values of 1.8 and 3.1 μM, respectively. These are binding affinities, not treatment concentrations or IC50 values. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AdipoR1 Kd 1.8 μM
AdipoR2 Kd 3.1 μM

Cellular Effect

Cell Line Activity Value Description Reference
RAW264.7 IC50 14.99 μM Anti-inflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of IL-1beta mRNA expression incubated for 12 hrs followed by LPS stimulation and measured after 6 hrs by RT-PCR method [PMID: 36215862]

AdipoRon Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of AdipoRon from 3 published references. In vitro models include differentiated C2C12 mouse myotubes.

AdipoRon In Vitro Studies

In C2C12 myotubes, AdipoRon increased AMPK phosphorylation, and AdipoR1 knockdown attenuated the response. It did not further increase AMPK phosphorylation at a maximal adiponectin concentration, indicating a context-dependent response ceiling. [1]

In stimulated BV2 microglia, AdipoRon reduced inflammatory cytokine transcription, IL-6/TNF-α secretion and NO production across a 1–50 μM concentration series. The findings describe cell-assay readouts; viability-normalized anti-inflammatory activity was not established by these assays. [2]

AdipoRon binding to human adiponectin receptors

Biochemical assay · Purified human AdipoR1 and AdipoR2 reconstituted in liposomes and immobilized on an SA sensor chip [1]

Saturable receptor binding was measured by surface plasmon resonance. A rhodopsin receptor control was reported as nonreactive in SI. These affinity endpoints are not cellular EC50 or IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Equilibrium binding to AdipoR1Kd 1.8 μM[1]
Equilibrium binding to AdipoR2Kd 3.1 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.49–31.25 μM
Method
Surface plasmon resonance (BIAcore X100)
Reported limits
Binding exposure duration, replicate n and compound solvent are not specified in the adopted figure caption/relevant extracted binding-method passage.
Methods and source locations

Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon

Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.

Figure 1a,j,k and caption; main receptor-binding paragraph; SI Binding assays

Equilibrium binding to AdipoR1: SPR equilibrium fit — Figure 1j; SI Binding assays

Equilibrium binding to AdipoR2: SPR equilibrium fit — Figure 1k; SI Binding assays

AMPK phosphorylation and receptor dependence in myotubes

Cell-based study · Differentiated C2C12 mouse myotubes [1]

AdipoRon increased AMPK phosphorylation; AdipoR1 siRNA reduced the response relative to unrelated siRNA. Compound 165073 was an inactive comparator and AICAR served as a mechanistically distinct positive control. AdipoRon did not further raise phosphorylation in the presence of maximal adiponectin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AMPK phosphorylation and AdipoR1-siRNA attenuationQualitative response Increased phosphorylation; reduced response with AdipoR1 siRNA[1]
Additional AMPK phosphorylation with maximal adiponectinQualitative limiting result No additional increase with 50 μg ml−1 adiponectin[1]

Literature-Reported Treatment Conditions

Treatment concentration
Dose response: 0.05–50 μM; siRNA comparison: 25 μM
Exposure duration
5 min for AdipoRon exposure
Method
Immunoblot of phosphorylated AMPK normalized to total AMPK
Reported limits
Compound vehicle is not identified in the adopted caption/relevant extracted methods. n=4 for Figure 1b,c,e; n=3 for Figure 1d; values mean ± s.e.m., not necessarily independent biological preparations.
Methods and source locations

Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon

Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.

Figure 1b–e and caption; Methods Summary Studies with C2C12 cells; SI RNA interference and immunoblotting

AMPK phosphorylation and AdipoR1-siRNA attenuation: Immunoblot; unrelated siRNA control — Figure 1b,c; SI RNA interference

Additional AMPK phosphorylation with maximal adiponectin: Immunoblot; adiponectin-alone comparison — Figure 1e and caption

Inflammatory readouts in stimulated microglia

Cell-based study · Murine BV2 microglial cells stimulated with purified lipopolysaccharide [2]

Compared with stimulated vehicle controls, AdipoRon lowered cytokine transcription and IL-6/TNF-α secretion and reduced NO production. Responses varied by endpoint and concentration; a universal significant effect at every dose is not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cytokine transcription, cytokine secretion and NO productionQualitative concentration response Reduced inflammatory readouts across the tested concentration series[2]

Literature-Reported Treatment Conditions

Treatment concentration
1, 10 and 50 μM; 0 μM vehicle comparator
Exposure duration
1 h pretreatment; subsequent readouts at 4 h (mRNA), 6 h (secreted cytokines), or 24 h (NO)
Method
qRT-PCR, ELISA and colorimetric NO assay
Vehicle
DMSO; Methods 2.6 identifies 1% DMSO control
Reported limits
Figure 7 reports n=3, mean ± SEM, without establishing independent biological versus technical replication. A viability-normalized response is not established in these adopted assays.
Methods and source locations

Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon

Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.

Methods 2.4,2.6,2.9–2.12; Results 3.5; Figure 7A–F and caption

Cytokine transcription, cytokine secretion and NO production: Figure 7: transcription relative to Actin; ELISA for IL-6 and TNF-α; NO assay; one-way ANOVA with Bonferroni tests — Figure 7A–F and caption; Results 3.5

AdipoRon In Vivo Studies

Metabolic effects depended on the mouse regimen. Daily subcutaneous AdipoRon at 5 mg kg−1 improved glucose tolerance and reduced hepatic triglycerides after 10 days in HFD-fed mice. A separate 20-day cohort showed worsened clamp-measured insulin sensitivity, including a reported 27.3% reduction in steady-state glucose infusion rate versus vehicle, despite no significant GTT AUC change. The cohorts also differed in total HFD exposure, so duration alone cannot explain the contrast. [3]

Short-course AdipoRon in diet-induced metabolic dysfunction

Animal study · 8-week-old male C57BL/6J mice; HFD for 4 weeks, with treatment during the last 10 days [3]

The 10-day cohort showed improved glucose tolerance and lower hepatic triglycerides and circulating free fatty acids relative to vehicle, without significant changes in body weight, food intake or fat measures.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Glucose tolerance, hepatic triglycerides, serum free fatty acids, body compositionQualitative controlled response Improved glucose tolerance; lower liver TG and FFA; no significant body-weight/food-intake/fat changes[3]

Conditions shared by the study groups

Route
Subcutaneous injection
Frequency
Daily
Treatment course
10 days; last 10 days of 4-week HFD
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AdipoRon monotherapy
5 mg kg−1 body weight per day
HFD-fed DMSO vehicle groupImproved GTT; decreased liver TG and serum FFA; no significant body-weight or food-intake change[3]
AdipoRon monotherapy
Model: Male C57BL/6J mice fed a 60%-calorie high-fat diet
Reported limits: AdipoRon supplier, catalog/lot, formulation concentration and group n are not specified in the adopted main-text methods/figure caption. No n inferred from plotted points.
Methods and source locations

Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon

Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.

Figure 1A–O and caption; Results short-term administration; Experimental procedures Animal models, AdipoRon treatment, GTT, Quantification and statistical analysis

Glucose tolerance, hepatic triglycerides, serum free fatty acids, body composition: Intraperitoneal GTT and biochemical/body-composition assays — Figure 1B–K; Results short-term administration

AdipoRon monotherapy · Figure 1 and caption; Experimental procedures Animal models and AdipoRon treatment

Prolonged AdipoRon worsened insulin sensitivity in HFD-fed mice

Animal study · Male C57BL/6J mice; HFD for 18 days before 20-day treatment, with HFD continued [3]

In the 20-day cohort, monotherapy reduced steady-state glucose infusion rate during clamping by 27.3% versus vehicle. Liver and muscle lipid accumulation and body weight increased. GTT AUC and fasting glucose did not significantly differ. The result limits a general claim of sustained metabolic benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Steady-state glucose infusion rate versus vehicleRelative reduction 27.3%[3]
Glucose tolerance, fasting glucose and lipid accumulationQualitative controlled response GTT AUC and fasting glucose not significantly changed; liver/muscle lipid accumulation increased[3]

Conditions shared by the study groups

Route
Subcutaneous injection
Frequency
Daily
Treatment course
20 days after 18 days of HFD
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AdipoRon monotherapy
5 mg kg−1 body weight per day
HFD-fed DMSO vehicle groupReduced clamp glucose infusion rate; increased tissue lipid and body weight; no significant GTT AUC or fasting glucose difference[3]
AdipoRon monotherapy
Model: Male C57BL/6J mice fed a 60%-calorie high-fat diet
Reported limits: AdipoRon supplier, catalog/lot, formulation concentration and group n are not specified in the adopted main-text methods/figure caption. No n inferred from plotted points.
Methods and source locations

Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon

Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.

Figure 5A–T and caption; Results long-term administration; Experimental procedures Animal models, AdipoRon treatment, hyperinsulinemic–euglycemic clamp, statistics

Steady-state glucose infusion rate versus vehicle: Hyperinsulinemic–euglycemic clamp; percentage explicitly reported in Results, not inferred from curve — Figure 5O,P and Results long-term administration

Glucose tolerance, fasting glucose and lipid accumulation: GTT; fasting biochemistry; tissue lipid assays — Figure 5G,J,K,M,N; Results long-term administration

AdipoRon monotherapy · Figure 5 and caption; Experimental procedures Animal models and AdipoRon treatment

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 924416-43-3
Applications AdipoR1 and AdipoR2 agonist
Formula C27H28N2O3
Molecular Weight 428.52
SMILES
C1CN(CCC1NC(=O)COC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CC4=CC=CC=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 77 mg/mL (179.69 mM)
Water Insoluble
Ethanol 45 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AdipoRon Research References

  1. [1] Okada-Iwabu M, Yamauchi T, Iwabu M, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity Nature (2013). PMID: 24172895 DOI: 10.1038/nature12656 Source material
  2. [2] Yan W, Gao S, Zhang Q, et al. AdipoRon Inhibits Neuroinflammation Induced by Deep Hypothermic Circulatory Arrest Involving the AMPK/NF-κB Pathway in Rats Pharmaceutics (2022). PMID: 36432657 DOI: 10.3390/pharmaceutics14112467 Source material
  3. [3] Wang Y, Liu H, Zhang R, et al. AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21-mediated time-dependent mechanisms The Journal of biological chemistry (2022). PMID: 35090894 DOI: 10.1016/j.jbc.2022.101641 Source material

Publications

4 publications citing this product

  1. Zongmeng Zhang, .et al. , Biocell, 2026, 50(1):1-10
  2. Weidong Yan, .et al. , Pharmaceutics, 2022, Nov 15;14(11):2467 PMID: 36432657
  3. Yunjing Yan, .et al. , J Pathol, 2022, Jun;257(2):146-157 PMID: 35072951
  4. Uchida T, .et al. , J Ocul Pharmacol Ther, 2019, Aug 28 PMID: 31460821

Added to your cart

View Cart Checkout
Loading...